Navigation Links
Simple, 2-question survery accurately screens cancer patients for depression
Date:9/23/2013

MAYWOOD, Il. -- Cancer patients can be accurately screened for major depression with a simple two-question survey, according to a study presented Sept. 23 at the American Society for Radiation Oncology's 55th Annual Meeting.

The two-question screening test proved to be as accurate as a longer nine-question screening test.

The study was presented at plenary session by William Small, Jr., MD, FASTRO, chair of the Department of Radiation Oncology of Loyola University Medical Center.

"We found that a two-question survey can effectively screen for depression," Small said. "We hope this will prompt more centers to screen for depression, and to refer patients for treatment when necessary."

The two-question survey asks whether, over the last two weeks, a patient has experienced:

  • Little interest or pleasure in doing things
  • Feeling down, depressed or hopeless

For each question, the patient can answer not at all (worth zero points); several days (1 point); more than half the days (two points); or nearly every day (3 points). A patient who scores a total of three or more points on both questions is considered to be at risk for being depressed.

The study included 455 cancer patients receiving radiation therapy at 37 centers in the United States. Patients were surveyed before or within two weeks of receiving their first radiation treatment. Sixteen percent screened positive for depression.

For comparison purposes, patients who screened positive were administered an in-depth telephone interview known as SCID, which is considered the gold standard for diagnosing depression. A random sample of patients who screened negative for depression also underwent the SCID interview. (SCID stands for Structured Clinical Interview for DSM IV Disorders.)

The two-question survey consists of the first two questions of the nine-question Patient Health Questionnaire. The study found that the abbreviated two-question survey was just as accurate as the full nine-question survey. In statistical terms, both surveys had an "area under the curve" of 0.83. (A 100 percent accurate test would have an area under the curve of 1.0.)

The two-question screening test was more accurate than two other screening tests researchers administered. These less-accurate screening tests are the Hopkins Symptom Checklist (0.79 area under the curve) and the National Comprehensive Cancer Network Distress Thermometer (0.60 area under the curve).

The study found that 78 percent of centers routinely screen patients for depression at the radiation therapy facility, with 51 percent screening at the initial visit. Mental health services were available at 68 percent of radiation therapy facilities. However, 67 percent of sites offered only social workers; 17 percent offered psychologists and 22 percent offered psychiatrists.

"We think the results of this large, nationwide trial will have a major impact on how cancer patients are screened for depression," Small said.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. The Fight Against West Nile Virus Begins Again: Learn Simple, Effective Tips to Protect Yourself and Family
2. Tiny.ms Offers Simple, Secure and Feature-Filled New Way to Shorten URLs
3. Simple, Two-Question Survery Accurately Screens Cancer Patients for Depression
4. Unique approach needed to accurately assess health of young adult cancer survivors
5. Advanced CT scans accurately assess coronary blockages
6. PET imaging used to more accurately manage treatment, predict survival for patients with gliomas
7. Dr. Neil McLeod, a West Hollywood Dentist, Announces a Development of a New Dental Instrument to Help Dentists Fit Crowns and Onlays More Accurately
8. Dual energy CT accurately identifies ACL tears in emergency department
9. Data suggests Abbotts test may help more accurately diagnose heart attacks in women
10. Early Study Hints at Link Between Certain Sunscreens, Endometriosis
11. Repelling the rays: New American Chemical Society video on sunscreens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood ... study appearing online in the journal Radiology. , Heart disease and brain disease exact ... to the rapidly aging population. Damage to both organs often occurs at a subclinical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
(Date:12/7/2016)... ... 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering insurance ... launching a charity drive to raise funds that will benefit the Marine Corps League. ... and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive ... Currently 5 biosimilar version of Lantus are commercially available in ... , Czech Republic , Estonia , ... Slovakia , United Kingdom for the treatment ... in 2014. Lantus is the brand name for Insulin Glargine, a ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... -- A new investigational drug originally developed for type 2 ... of the world,s first treatment to impede the progression of ... in the journal Science Translational Medicine . ... for millions of people living with Parkinson,s disease," says ... Research Institute,s Center for Neurodegenerative Science , chairman ...
Breaking Medicine Technology: